Euronext publishes its 2025 Universal Registration Document Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 27 March 2026 – Euronext today announced that it has filed its 2025 Universal Registration Document, prepared in ESEF format (European Single Electronic Format), including the 2025 Annual Financial Statements and Directors’ Report to the Stichting Autoriteit Financiële Markten (the “AFM”), on 27 March 2026, as competent authority under Regulation (EU) 2017/1129. The 2025 Universal Registration Document has been filed in English and is available in ESEF format on Euronext’s website at: https://www.euronext.com/en/investor-relations/financial-information/financial-reports Printed copies of the official version filed to the AFM in ESEF format are available at the registered office of Euronext N.V.: Beursplein 5...

The annual general meeting of Kaldalón hf. (“Kaldalón” or the “Company”), held on 26 March 2026, approved an authorisation for the Board of Directors to acquire shares in the Company so that, subject to applicable legal requirements, the Company may hold up to 10% of its share capital. The purpose of the authorisation is to support market making in the Company’s shares and/or to establish a formal share buyback programme in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council on market abuse, as well as Commission Delegated Regulation (EU) 2016/1052, cf. Act No. 60/2021 on Measures Against Market Abuse. The authorisation granted by the annual general meeting is valid until 30 June 2027. On the basis of the above resolution of the annual general meeting, the Board of Directors of Kaldalón...

27 March 2026, 17:45 CET ArcelorMittal has published the statutory financial statements of ArcelorMittal parent company for the year ended 31 December 2025. These financial statements have been filed with the electronic database of the Luxembourg Stock Exchange (www.bourse.lu) and are available on http://corporate.arcelormittal.com in the Corporate Library. ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrated steel and mining companies with a presence in 60 countries and primary steelmaking operations in 14 countries. It is the largest steel producer in Europe, among the largest in the Americas, and has a growing presence in Asia through its joint venture AM/NS India. ArcelorMittal sells its products to a diverse range of customers including the automotive, engineering, construction and machinery industries,...

MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized on two of The Globe and Mail’s Report on Business magazine’s 2026 national benchmarks:Canada’s Top Growing Women-Led Companies, now in its second year, which highlights Canadian women-led businesses; and Women Lead Here, now in its seventh year, which identifies Canadian public companies demonstrating industry leading levels of executive gender diversity.“Being recognized in both Canada’s Top Growing Women-Led Companies and Women Lead Here is a meaningful milestone for Knight,” said Samira Sakhia, President and Chief Executive Officer of Knight. “This is our first year being named among Canada’s Top Growing Women-Led Companies, a reflection of our sustained growth and the entrepreneurial...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Cambridge Acquisition Corp. (Nasdaq: CAQUU) (the “Company”) announced today that, commencing March 30, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “CAQ” and “CAQUW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAQUU.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these...

The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a technical and legal nature relating to the main investor who has repeatedly expressed its intention to swiftly complete the transaction. The Board therefore expects the transaction to be completed in Q2 2026. The proceeds of the transaction will materially strengthen the Company’s balance sheet and support ongoing growth momentum. Please...

Adds Cash to the Balance Sheet  The Company to Report Fourth Quarter 2025 Financial Results on March 31, 2026 BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it has completed the refinancing (the “Refinancing”) of its former senior secured credit facility (the “Former 1st Lien Credit Facility”) and its former second lien credit facility (the “Former 2nd Lien Credit Facility”) through the issuance of a $160 million senior secured term loan (the “Term Loan”) with funds managed by FocusGrowth Asset Management, along with other members of a loan syndicate. FG Agency Lending LLC, a subsidiary of FocusGrowth Asset Management, acted as administrative agent for the Term Loan. The Term Loan...

Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in...